Distinct apoptotic responses imparted by c-myc and max

Chadd Nesbit, Saijun Fan, Hong Zhang, Edward V. Prochownik

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The c-myc oncoprotein accelerates programmed cell death (apoptosis) after growth factor deprivation or pharmacological insult in many cell lines. We have shown that max, the obligate c-myc heterodimeric partner protein, also promotes apoptosis after serum withdrawal in NIH3T3 fibroblasts or cytokine deprivation in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. We now show that c-myc- and max-overexpressing 32D cells differ in the nature of their apoptotic responses after IL-3 removal or treatment with chemotherapeutic compounds. In the presence of IL-3, c-myc overexpression enhances the sensitivity of 32D cells to Etoposide (Sigma, St Louis, MO), Adriamycin (Pharmacia, Columbus, OH), and Camptothecin (Sigma), whereas max overexpression increases sensitivity only to Camptothecin. Drug treatment of c-myc-overexpressing cells in the absence of IL-3 did not alter the spectrum of drug sensitivity other than to additively accelerate cell death. In contrast, enhanced sensitivity to Adriamycin, Etoposide, and Taxol (Bristol- Meyers Squibb, Princeton, NJ) was revealed in max-overexpressing cells concurrently deprived of IL-3. Differential rates of apoptosis were not strictly correlated with the ability of the drugs to promote G1 or G2/M arrest. Ectopic expression of Bcl-2 or Bcl-X(L) blocked drug-induced apoptosis in both cell lines. In contrast, whereas Bcl-2 blocked apoptosis in both cell lines in response to IL-3 withdrawal, Bcl-X(L) blocked apoptosis in max-overexpressing cells but not in c-myc-overexpressing cells. These results provide mechanistic underpinnings for the idea that c-myc and max modulate distinct apoptotic pathways.

Original languageEnglish (US)
Pages (from-to)1003-1010
Number of pages8
JournalBlood
Volume92
Issue number3
StatePublished - Aug 1 1998

Fingerprint

Interleukin-3
Apoptosis
Cells
Camptothecin
Etoposide
Cell death
Cell Line
Pharmaceutical Preparations
Doxorubicin
Cell Death
Drug therapy
Oncogene Proteins
Myeloid Cells
Fibroblasts
Paclitaxel
Intercellular Signaling Peptides and Proteins
Pharmacology
Cytokines
Serum
Proteins

All Science Journal Classification (ASJC) codes

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Nesbit, C., Fan, S., Zhang, H., & Prochownik, E. V. (1998). Distinct apoptotic responses imparted by c-myc and max. Blood, 92(3), 1003-1010.
Nesbit, Chadd ; Fan, Saijun ; Zhang, Hong ; Prochownik, Edward V. / Distinct apoptotic responses imparted by c-myc and max. In: Blood. 1998 ; Vol. 92, No. 3. pp. 1003-1010.
@article{df46b3b4385e4bffa639e8eac049aefb,
title = "Distinct apoptotic responses imparted by c-myc and max",
abstract = "The c-myc oncoprotein accelerates programmed cell death (apoptosis) after growth factor deprivation or pharmacological insult in many cell lines. We have shown that max, the obligate c-myc heterodimeric partner protein, also promotes apoptosis after serum withdrawal in NIH3T3 fibroblasts or cytokine deprivation in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. We now show that c-myc- and max-overexpressing 32D cells differ in the nature of their apoptotic responses after IL-3 removal or treatment with chemotherapeutic compounds. In the presence of IL-3, c-myc overexpression enhances the sensitivity of 32D cells to Etoposide (Sigma, St Louis, MO), Adriamycin (Pharmacia, Columbus, OH), and Camptothecin (Sigma), whereas max overexpression increases sensitivity only to Camptothecin. Drug treatment of c-myc-overexpressing cells in the absence of IL-3 did not alter the spectrum of drug sensitivity other than to additively accelerate cell death. In contrast, enhanced sensitivity to Adriamycin, Etoposide, and Taxol (Bristol- Meyers Squibb, Princeton, NJ) was revealed in max-overexpressing cells concurrently deprived of IL-3. Differential rates of apoptosis were not strictly correlated with the ability of the drugs to promote G1 or G2/M arrest. Ectopic expression of Bcl-2 or Bcl-X(L) blocked drug-induced apoptosis in both cell lines. In contrast, whereas Bcl-2 blocked apoptosis in both cell lines in response to IL-3 withdrawal, Bcl-X(L) blocked apoptosis in max-overexpressing cells but not in c-myc-overexpressing cells. These results provide mechanistic underpinnings for the idea that c-myc and max modulate distinct apoptotic pathways.",
author = "Chadd Nesbit and Saijun Fan and Hong Zhang and Prochownik, {Edward V.}",
year = "1998",
month = "8",
day = "1",
language = "English (US)",
volume = "92",
pages = "1003--1010",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

Nesbit, C, Fan, S, Zhang, H & Prochownik, EV 1998, 'Distinct apoptotic responses imparted by c-myc and max', Blood, vol. 92, no. 3, pp. 1003-1010.

Distinct apoptotic responses imparted by c-myc and max. / Nesbit, Chadd; Fan, Saijun; Zhang, Hong; Prochownik, Edward V.

In: Blood, Vol. 92, No. 3, 01.08.1998, p. 1003-1010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Distinct apoptotic responses imparted by c-myc and max

AU - Nesbit, Chadd

AU - Fan, Saijun

AU - Zhang, Hong

AU - Prochownik, Edward V.

PY - 1998/8/1

Y1 - 1998/8/1

N2 - The c-myc oncoprotein accelerates programmed cell death (apoptosis) after growth factor deprivation or pharmacological insult in many cell lines. We have shown that max, the obligate c-myc heterodimeric partner protein, also promotes apoptosis after serum withdrawal in NIH3T3 fibroblasts or cytokine deprivation in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. We now show that c-myc- and max-overexpressing 32D cells differ in the nature of their apoptotic responses after IL-3 removal or treatment with chemotherapeutic compounds. In the presence of IL-3, c-myc overexpression enhances the sensitivity of 32D cells to Etoposide (Sigma, St Louis, MO), Adriamycin (Pharmacia, Columbus, OH), and Camptothecin (Sigma), whereas max overexpression increases sensitivity only to Camptothecin. Drug treatment of c-myc-overexpressing cells in the absence of IL-3 did not alter the spectrum of drug sensitivity other than to additively accelerate cell death. In contrast, enhanced sensitivity to Adriamycin, Etoposide, and Taxol (Bristol- Meyers Squibb, Princeton, NJ) was revealed in max-overexpressing cells concurrently deprived of IL-3. Differential rates of apoptosis were not strictly correlated with the ability of the drugs to promote G1 or G2/M arrest. Ectopic expression of Bcl-2 or Bcl-X(L) blocked drug-induced apoptosis in both cell lines. In contrast, whereas Bcl-2 blocked apoptosis in both cell lines in response to IL-3 withdrawal, Bcl-X(L) blocked apoptosis in max-overexpressing cells but not in c-myc-overexpressing cells. These results provide mechanistic underpinnings for the idea that c-myc and max modulate distinct apoptotic pathways.

AB - The c-myc oncoprotein accelerates programmed cell death (apoptosis) after growth factor deprivation or pharmacological insult in many cell lines. We have shown that max, the obligate c-myc heterodimeric partner protein, also promotes apoptosis after serum withdrawal in NIH3T3 fibroblasts or cytokine deprivation in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. We now show that c-myc- and max-overexpressing 32D cells differ in the nature of their apoptotic responses after IL-3 removal or treatment with chemotherapeutic compounds. In the presence of IL-3, c-myc overexpression enhances the sensitivity of 32D cells to Etoposide (Sigma, St Louis, MO), Adriamycin (Pharmacia, Columbus, OH), and Camptothecin (Sigma), whereas max overexpression increases sensitivity only to Camptothecin. Drug treatment of c-myc-overexpressing cells in the absence of IL-3 did not alter the spectrum of drug sensitivity other than to additively accelerate cell death. In contrast, enhanced sensitivity to Adriamycin, Etoposide, and Taxol (Bristol- Meyers Squibb, Princeton, NJ) was revealed in max-overexpressing cells concurrently deprived of IL-3. Differential rates of apoptosis were not strictly correlated with the ability of the drugs to promote G1 or G2/M arrest. Ectopic expression of Bcl-2 or Bcl-X(L) blocked drug-induced apoptosis in both cell lines. In contrast, whereas Bcl-2 blocked apoptosis in both cell lines in response to IL-3 withdrawal, Bcl-X(L) blocked apoptosis in max-overexpressing cells but not in c-myc-overexpressing cells. These results provide mechanistic underpinnings for the idea that c-myc and max modulate distinct apoptotic pathways.

UR - http://www.scopus.com/inward/record.url?scp=0032147114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032147114&partnerID=8YFLogxK

M3 - Article

C2 - 9680370

AN - SCOPUS:0032147114

VL - 92

SP - 1003

EP - 1010

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -

Nesbit C, Fan S, Zhang H, Prochownik EV. Distinct apoptotic responses imparted by c-myc and max. Blood. 1998 Aug 1;92(3):1003-1010.